Drugs / HL1113R1
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07568652 | Oct → Nov 2024 | hypertensive disorder, type 2 diabetes mellitus | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07598968 | Jun → Jul 2023 | hypertensive disorder, type 2 diabetes mellitus | Hanlim Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07552389 | Dec 2025 → Dec 2028 expected | essential hypertension, type 2 diabetes mellitus | Hanlim Pharm. Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HL1113R1 | “HL1113R1 + placebo of HL1113T1, HL1113T2, HL1113R2, once daily, administered for 12 weeks” NCT07552389 ↗2“Period 1: HL1113-R1, once daily, administered for 7 days” NCT07598968 ↗ “Period 1 : HL1113R1 + HL1113R2, once daily” NCT07568652 ↗ |
| Route | Oral | “single oral dose” NCT07568652 ↗ |